[1]
|
T. Ferguson, N. Wilcken, R. Vagg, D. Ghersi and A. K. Nowak, “Taxanes for Adjuvant Treatment of Early Breast Cancer,” Cochrane Review, Vol. 17, No. 4, 2007, p. 4421.
doi:10.1002/14651858.
|
[2]
|
M. De Laurentiis, G. Arpino and E. Massarelli, et al., “A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer,” Clinical Cancer Research, Vol. 17, No. 15, 2005, pp. 4741-4748.
doi:10.1158/1078-0432.CCR-04-2569
|
[3]
|
M. Martin, T. Pienkowski and J. Mackey, et al., “Adjuvant Docetaxel for Node-Positive Breast Cancer,” The New England Journal of Medicine, Vol. 352, 2005, pp. 2302-2313. doi:10.1056/NEJMoa043681
|
[4]
|
P. Francis, J. Crown, A. Di Leo and M. Buyse, et al., “Adjuvant Chemotherapy with Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02-98 Randomized Trial,” Journal of the National Cancer Institution, Vol. 100, No. 2, 2008, pp. 121-133.
doi:10.1093/jnci/djm287
|
[5]
|
M. Martin, A. Lluch and M. A. Segui, et al., “TAC versus FAC as Adjuvant Chemotherapy for High-Risk Node-Negative Breast Cancer: Results of the GEICAM 9805 Trial,” Annual Oncology, Vol. 19, 2008, p. 1830.
|
[6]
|
S. Jones, F. A. Holmes and J. O’Shaughnessy, “Docetaxel with Cyclophosphamide Is Associated with an Overall Survival Benefit Compared with Doxorubicin and Cyclophosphamide: 7-Year Follow-up of US Oncology Research Trial 9735,” Journal of Clinical Oncology, Vol. 27, No. 8, 2009, pp. 1177-1183.
doi:10.1200/JCO.2008.18.4028
|
[7]
|
I. C. Henderson, D. A. Berry and G. D. Demetri, “Improved Outcomes from Adding Sequential Paclitaxel but not from Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients with Node-Positive Primary Breast Cancer,” Journal of Clinical Oncology, Vol. 21, No. 6, 2003, pp. 976-983.
doi:10.1200/JCO.2003.02.063
|
[8]
|
E. P. Mamounas, J. Bryant and B. Lembersky, “Paclitaxel after Doxorubicin plus Cyclophosphamide as Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results from NSABP B-28,” Journal of Clinical Oncology, Vol. 23, No. 16, 2005, pp. 3686-3696.
doi:10.1200/JCO.2005.10.517
|
[9]
|
L. Gianni, J. Baselga and W. Eiermann, et al., “Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, as Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer,” Journal of Clinical Oncology, Vol. 27, No. 15, 2009, pp. 2474-2481. doi:10.1200/JCO.2008.19.2567
|
[10]
|
A. Polyzos, N. Malamos and I. Boukovinas, et al., “FEC versus Sequential Docetaxel Followed by Epirubicin/ Cyclophosphamide as Adjuvant Chemotherapy in Women with Axillary Node-Positive Early Breast Cancer: A Randomized Study of the Hellenic Oncology Research Group (HORG),” Breast Cancer Research and Treatment, Vol. 119, No. 1, 2010, pp. 95-104.
doi:10.1007/s10549-009-0468-0
|
[11]
|
H. Roche, P. Fumoleau and M. Spielmann, “Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial,” Journal of Clinical Oncology, Vol. 24, No. 36, 2006, pp. 5664-5671.
doi:10.1200/JCO.2006.07.3916
|
[12]
|
M. Martin, A. Rodriguez-Lescure and A. Ruiz, “Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer,” Journal of the National Cancer Institution, Vol. 100, No. 11, 2008, pp. 805-814.
doi:10.1093/jnci/djn151
|
[13]
|
T. R. Evans, A. Yellowlees and E. Foster, et al., “Phase III Randomized Trial of Doxorubicin and Docetaxel versus Doxorubicin and Cyclophosphamide as Primary Medical Therapy in Women with Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study,” Journal of Clinical Oncology, Vol. 23, No. 13, 2005, pp. 2988-2895.
doi:10.1200/JCO.2005.06.156
|
[14]
|
L. J. Goldstein, A. O’Neill and J. A. Sparano, et al., “Concurrent Doxorubicin Plus Docetaxel is not More Effective than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer with 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197,” Journal of Clinical Oncology, Vol. 26, No. 25, 2008, pp. 4092-4099.
doi:10.1200/JCO.2008.16.7841
|
[15]
|
A. U. Buzdar, S. E. Singletary and V. Valero, et al., “Evaluation of Paclitaxel in Adjuvant Chemotherapy for Patients with Operable Breast Cancer: Preliminary Data of a Prospective Randomized Trial,” Clinical Cancer Research, Vol. 8, 2002, pp. 1073-1079.
|
[16]
|
G. Fountzilas, D. Skarlos and U. Dafni, “Postoperative Dose-Dense Sequential Chemotherapy with Epirubicin, Followed by CMF with or without Paclitaxel, in Patients with High-Risk Operable Breast Cancer: A Randomized Phase III Study Conducted by the Hellenic Cooperative Oncology Group,” Annals of Oncology, Vol. 16, No. 11, 2005, pp. 1762-1771. doi:10.1093/annonc/mdi366
|
[17]
|
H. D. Bear, S. Anderson and R. E. Smith, et al., “Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27,” Journal of Clinical Oncology, Vol. 24, No. 13, 2006, pp. 2019-2027.
doi:10.1200/JCO.2005.04.1665
|
[18]
|
A. R. Bianco, A. De Matteis and L. Manzione, “Sequential Epirubicin-Docetaxel-CMF as Adjuvant Therapy of Early Breast Cancer: Results of the Taxit216 Multicenter Phase III Trial,” Journal of Clinical Oncology, Vol. 24, No. 18, 2006, p. 520.
|
[19]
|
M. J. Burnell, M. N. Levine and J. A. Chapman, et al., “Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer,” Journal of Clinical Oncology, Vol. 28, No. 1, 2010, pp. 77-82.
doi:10.1200/JCO.2009.22.1077
|
[20]
|
P. Ellis, P. Barrett-Lee and L. Johnson, et al., “Sequential Docetaxel as Adjuvant Chemotherapy for Early Breast Cancer (TACT): An Open-Label, Phase III, Randomised Controlled Trial,” Lancet, Vol. 373, 2009, pp. 1681-1692.
doi:10.1016/S0140-6736(09)60740-6
|
[21]
|
D. A. Berry, C. Cirrincione and I. G. Henderson, et al., “Estrogen Receptor Status and Outcomes of Modern Chemotherapy for Patients with Node-Positive Breast Cancer,” The Journal of the American Medical Association, Vol. 295, No. 14, 2006, pp. 1658-1667.
doi:10.1001/jama.295.14.1658
|
[22]
|
D. F. Hayes, A. D. Thor and L. G. Dressler, et al., “Her2 and Response to Paclitaxel in Node Positive Breast Cancer,” The New England Journal of Medicine, Vol. 357, 2007, pp. 1496-1506. doi.org/10.1056/NEJMoa071167
|